Xanadu and Alberta U. seek better cancer drugs with quantum chips

Xanadu (NASDAQ/TSX: XNDU) is investing in pharmaceutical research through a new partnership with the University of Alberta to accelerate the design of compounds for photodynamic therapy, a cancer treatment that avoids chemotherapy side effects. The collaboration unites Xanadu’s quantum computing framework with the published work of Professor Alex Brown on benchmarking photosensitizer simulations. “Current methodologies for developing effective photosensitizers are hampered by several hurdles,” said Dr. Christian Weedbrook, Founder and Chief Executive Officer of Xanadu, adding that leveraging quantum computers could make the technology a competitive method for drug discovery. This partnership aims to strengthen Xanadu’s workflow for drug design and address increasingly sophisticated challenges in photosensitizer development. Xanadu and Alberta U.

Target Photosensitizer Challenges with Quantum Computing The collaboration focuses on accelerating the development of photosensitizers, light-activated compounds designed to selectively destroy tumor cells. Professor Brown’s research has identified limitations in current computational methods used to predict the effectiveness of these photosensitizers; standard techniques struggle to accurately model crucial interactions that determine their performance. Xanadu recently demonstrated the potential of quantum computers to simulate light-matter interactions within photosensitizers, revealing properties difficult to ascertain using classical approaches, including sensitivity to specific wavelengths and efficiency in triggering cell death. This builds on Xanadu’s existing open-source quantum computing platform, PennyLane, and represents an expansion of their quantum-based workflow for drug design. The partnership intends to address these hurdles by leveraging early fault-tolerant quantum computers to model complex light-matter interactions, potentially accelerating photodynamic drug discovery. Professor Brown emphasized the challenges inherent in modeling photosensitizers, noting that their performance relies on excited-state processes difficult to capture with standard computational methods. “By combining Xanadu’s quantum algorithm expertise with our experience in modeling photodynamic therapy systems, we’re excited to explore how fault-tolerant quantum computing could provide new tools for understanding and designing more effective light-activated cancer treatments,” said Professor Brown, Professor and Chair at the University of Alberta. This combined effort seeks to push the boundaries of drug development and simulations for application within the pharmaceutical industry. Current methodologies for developing effective photosensitizers are hampered by a variety of hurdles. By leveraging early fault-tolerant quantum computers to model critical light-matter interactions within photosensitizers, we are positioning quantum computing as a highly competitive method for accelerating photodynamic drug discovery. Dr. Christian Weedbrook, Founder and Chief Executive Officer of Xanadu Source: https://www.globenewswire.com/news-release/2026/08/13/3344358/0/en/xanadu-and-university-of-alberta-partner-to-accelerate-pharmaceutical-discoveries-with-quantum-computing.html Stay currentSee today’s quantum computing news on Quantum Zeitgeist for the latest breakthroughs in qubits, hardware, algorithms, and industry deals. Tags: Ivy Delaney Ivy Delaney has been working with neural networks and machine learning since the mid-nineties, back when a couple of hidden layers and a long afternoon of training counted as ambitious. She has watched the field go from academic curiosity to the thing quietly running underneath everything, and she brings that long view to quantum computing.

For Quantum Zeitgeist she covers the ground where the two fields meet. That means quantum machine learning and the variational algorithms it leans on, and it also means the less glamorous but more interesting story of classical machine learning already doing real work inside quantum machines, decoding error-correcting codes, calibrating noisy hardware and learning the error models that simulators depend on. She writes about the hardware those algorithms have to run on too, and about the post-quantum cryptography scramble that the same hardware has set off. Her stories typically start with the paper, whether that is peer-reviewed work, conference proceedings or an arXiv preprint, with the source linked so you can hold a claim up against the research it came from. She is unimpressed by benchmarks that will not say what they beat, and by demonstrations that only work in the press release. Latest Posts by Ivy Delaney: SEALSQ & Quobly Seal $5 Million Post-Quantum Security Deal August 13, 2026 Kagome metal’s quantum effects yield strong heat-to-power at zero field August 13, 2026 Quantum chip isolator cuts back-reflections by 30 decibels August 13, 2026